Targeting the R domain of coagulase by active vaccination protects mice against lethal Staphylococcus aureus infection

Qian, Mengying; Zhao, Taoran; Li, Ruihua; Yang, Qiaoling; Yu, Rui; Yin, Ying; Zai, Xiaodong; Li, Yaohui; Zhang, Jun; Xu, Junjie; Chen, Wei

doi:10.1016/j.micinf.2018.11.001

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A limitation in this study is the selection of hypovirulent strain B. abortus S19 as challenge strain for protection experiments [ 43 , 71 , 72 ]. B. abortus S19 was originally isolated as a virulent strain from a Jersey cow in 1923 and was found to become attenuated after being kept in the laboratory at room temperature for more than a year [ 41 , 42 ]. It can also infect humans, causing typical features of brucellosis, including acute febrile illness.…”

Section: Discussionmentioning

confidence: 99%

“…Three potential protective antigens of Brucella were selected for evaluation: Omp19, VirB8, and HlyD. Gene coding for the proteins was cloned from B. abortus 104 M as C-terminal His-tagged fusion protein and then expressed and purified as previously reported, with some modifications [ 42 ]. Briefly, the PCR products of target genes (without signal peptides) were purified and then cloned into a pEASY-Blunt E1 expression vector (TransGen).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology

Zai

Yin

Guo

et al. 2021

Vet Res

Self Cite

View full text Add to dashboard Cite

Brucella spp. are Gram-negative, facultative intracellular bacteria that cause brucellosis in humans and various animals. The threat of brucellosis has increased, yet currently available live attenuated vaccines still have drawbacks. Therefore, subunit vaccines, produced using protein antigens and having the advantage of being safe, cost-effective and efficacious, are urgently needed. In this study, we used core proteome analysis and a compositive RV methodology to screen potential broad-spectrum antigens against 213 pathogenic strains of Brucella spp. with worldwide geographic distribution. Candidate proteins were scored according to six biological features: subcellular localization, antigen similarity, antigenicity, mature epitope density, virulence, and adhesion probability. In the RV analysis, a total 32 candidate antigens were picked out. Of these, three proteins were selected for assessment of immunogenicity and preliminary protection in a mouse model: outer membrane protein Omp19 (used as a positive control), type IV secretion system (T4SS) protein VirB8, and type I secretion system (T1SS) protein HlyD. These three antigens with a high degree of conservation could induce specific humoral and cellular immune responses. Omp19, VirB8 and HlyD could substantially reduce the organ bacterial load of B. abortus S19 in mice and provide varying degrees of protection. In this study, we demonstrated the effectiveness of this unique strategy for the screening of potential broad-spectrum antigens against Brucella. Further evaluation is needed to identify the levels of protection conferred by the vaccine antigens against wild-type pathogenic Brucella species challenge.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology

Zai

Yin

Guo

et al. 2021

Vet Res

Self Cite

View full text Add to dashboard Cite

show abstract

<p>Recent advances in <em>Staphylococcus aureus</em> infection: focus on vaccine development</p>

Ansari

Jha

Mishra

et al. 2019

IDR

View full text Add to dashboard Cite

Staphylococcus aureus normally colonizes the nasal cavity and pharynx. After breaching the normal habitat, the organism is able to cause a number of infections at any site of the body. The development of antibiotic resistance has created a global challenge for treating infections. Therefore, protection by vaccines may provide valuable measures. Currently, several vaccine candidates have been prepared which are either in preclinical phase or in early clinical phase, whereas several candidates have failed to show a protective efficacy in human subjects. Approaches have also been made in the development of monoclonal or polyclonal antibodies for passive immunization to protect from S. aureus infections. Therefore, in this review we have summarized the findings of recently published scientific literature to make a concise report.

show abstract

Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production

et al. 2022

View full text Add to dashboard Cite

Tetanus toxoid (TTd) plays an important role in the pharmaceutical world, especially in vaccines. The toxoid is obtained after formaldehyde treatment of the tetanus toxin. In parallel, current emphasis in the drug discovery field is put on producing well-defined and safer drugs, explaining the interest in finding new alternative proteins. The tetanus toxin fragment C (TTFC) has been extensively studied both as a neuroprotective agent for central nervous system disorders owing to its neuronal properties and as a carrier protein in vaccines. Indeed, it is derived from a part of the tetanus toxin and, as such, retains its immunogenic properties without being toxic. Moreover, this fragment has been well characterized, and its entire structure is known. Here, we propose a systematic review of TTFC by providing information about its structural features, its properties and its methods of production. We also describe the large uses of TTFC in the field of drug discovery. TTFC can therefore be considered as an attractive alternative to TTd and remarkably offers a wide range of uses, including as a carrier, delivery vector, conjugate, booster, inducer, and neuroprotector.

show abstract

Targeting the R domain of coagulase by active vaccination protects mice against lethal Staphylococcus aureus infection

Cited by 3 publications

References 35 publications

Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology

Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology

<p>Recent advances in <em>Staphylococcus aureus</em> infection: focus on vaccine development</p>

Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production

Contact Info

Product

Resources

About